.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has submitted to debut on everyone market.The Eli Lilly-partnered biotech intend to list on the Nasdaq under the symbolic representation “BIOA,” depending on to records submitted with the Securities and Swap Percentage. The provider has actually certainly not openly shared an anticipated financial volume for the offering.The clinical-stage provider proclaims lead applicant azelaprag, a by mouth supplied little particle slated to enter into period 2 screening in combo with semaglutide– offered by Novo Nordisk under brand name Wegovy for weight management– in the first half of next year. Semaglutide is actually also marketed as Ozempic as well as Rybelsus through Novo for diabetes.
Apelin receptor agonist azelaprag is developed to integrate well along with GLP-1 medications, improving weight management while preserving muscular tissue mass. The investigational medicine was found to become well-tolerated among 265 people around eight phase 1 trials, according to BioAge.Previously, BioAge gathered the assistance of Lilly to manage a trial blending azelaprag with the Major Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is industried for diabetes mellitus as Mounjaro and also Zepbound for weight loss. The partners are actually currently conducting a stage 2 trial of azelaprag and tirzepatide, with topline results expected in the 3rd quarter of 2025.The biotech is actually also organizing a the hormone insulin sensitivity proof-of-concept trial evaluating azelaprag as a monotherapy in the initial half of upcoming year to assist prospective indication growth.
Additionally, the company prepares to inquire the FDA for consent in the 2nd half of 2025 to release human testing for an NLRP3 prevention targeting metabolic illness as well as neuroinflammation.BioAge’s expected transfer to the general public market complies with a mild uptick in prepared biotech IPOs coming from Bicara Therapeutics and Zenas Biopharma. Zooming out, the recent IPO landscape is actually a “blended picture,” with high-grade companies still debuting on everyone markets, simply in lessened amounts, depending on to PitchBook.